Vincent C. Tam

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Unintended Medication Discrepancies at the Time of Hospital Admission

Patricia Cornish, Simon R. Knowles, Romina Marchesano et al. · Archives of Internal Medicine · 2005 · 962 citations

Medicine, Clinical Pharmacy, Internal Medicine +13

Oligomerization of μ- and δ-Opioid Receptors

Susan R. George, Theresa Fan, Zhidong Xie et al. · Journal of Biological Chemistry · 2000 · 552 citations · Full text

Medicine, Molecular Biology, Pharmacology +15

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2022 · 400 citations

Pharmacy, Oncology, Pharmacotherapy +17

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

Medicine, Oncology, Pharmacotherapy +16